Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment — not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing any serious adverse events · the management of chronic obstructive pulmonary disease
Multi‐component intervention showed no clear difference in adverse events: number of people experiencing a serious adverse event compared with other intervention or routine, usual care or control treatment (low certainty).
1 finding from 1 review
Serious adverse events, ‐ in total population randomised ‐ hypoglycaemia · critically ill patients
Intensive insulin therapy leads to higher serious adverse events, ‐ in total population randomised ‐… compared with conventional insulin therapy (high certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events related to the use of physical restraints ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
Adverse events experienced at short or long term ‐ Serious adverse events 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in adverse events experienced at short or long term ‐ Serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Serious or severe adverse events N of participants with positive severe adverse events · people with acne scars
It is very uncertain whether chemical peeling changes serious or severe adverse events N of participants with positive… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events a. Serious adverse events b. Discontinuation of trial because of adverse events · obese children and adolescents
The intervention showed no clear difference in adverse events a. Serious adverse events b. Discontinuation of trial… (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (such as donor site morbidity, failure of graft including re‐rupture) at 2 years · Adults with acute anterior cruciate ligament (ACL) injuries (young, active individuals)
1 finding from 1 review